ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 132

FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs

Koichi Okamura1, Yukio Yonemoto2, Tetsuya Kaneko3, Kimihiko Takeuchi4, Tsutomu Kobayashi1 and Kenji Takagishi1, 1Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, 3Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan, 4Department of Rheumatology, Isesaki Fukushima Hospital, Isesaki, Gunma, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, imaging techniques, Lymph node, positron emission tomography (PET) and rheumatoid arthritis, synovium

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). The development of molecular imaging methods would be beneficial, especially in RA patients. In the present study, we evaluated whether the FDG uptake of the affected joints and the axillary lymph nodes (AxLN) represented by the standardized uptake value (SUV) correlated with the clinical assessment of patients with RA. In addition, we evaluated if there was a correlation between the differences in the SUV and the improvement of the clinical findings in RA patients receiving anti-TNF therapies.

Methods: Forty-two patients (10 male, 32 female; average age: 55.67 (18-74) years) who underwent anti-TNF therapies (infliximab (IFX) for 17 patients, etanercept (ETN) for 14 patients and adalimumab (ADA) for 11 patients), were enrolled in this study. The average disease duration of these patients was 11.7 (0.6-49) years. Clinical disease activity was assessed by using disease activity scoring (DAS) 28, DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and numbers of 28 tender and swollen joints count (TJC, SJC) and measuring erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum matrix metalloproteinase-3 (MMP-3) and rheumatoid factor (RF) at baseline (0M) and after 6 month (6M) of the therapies. FDG-PET/CT was performed 0M and 6M. The PET images were interpreted by two experienced nuclear physicians and increased FDG uptake in bilateral shoulder, elbow, wrist, hip, knee, and ankle joints and bilateral AxLN were recorded. Therapeutic response was evaluated by the changes in the sum of the maximal SUV (total SUVmax) of all 12 measured joints and the clinical findings.

Results: Before treatment, the total SUVmax was correlated with the DAS28 (r=0.532,p=0.001), DAS28-CRP (r=0.529,p<0.001), SDAI (r=0.491, p=0.001), CDAI (r=0.457, p=0.002), ESR (r=0.506, p=0.001), CRP (r=0.385, p=0.012), TJC (r=0.416, p=0.007) and SJC (r=0.467, p=0.002), respectively. The SUVs of AxLN were correlated with the SUV of the ipsilateral wrist joints. The ΔSUV, the difference in the total SUVmax before and after treatment, significantly correlated with the ΔDAS28 (r=0.498, p=0.001), ΔDAS28-CRP (r=0.517, p<0.001), ΔSDAI (r=0.550, r<0.001), ΔCDAI (r=0.534, p<0.001), ΔESR (r=0.485, p=0.001), ΔCRP (r=0.437, p=0.003), ΔTJC (r=0.447, p=0.003) and ΔSJC (r=0.525, p<0.001), respectively. ΔSUV of AxLN did not correlate with ΔCRP, ΔESR and ΔMMP-3, however, correlated with the Δ SUV of the same or other side of the wrist joint.

Conclusion: FDG-PET can image the extent of inflammation in patients with RA. In addition, the FDG uptake of the axillary lymph nodes might reflect the disease activity especially in the wrist joints. FDG-PET can be used to evaluate the response of RA patients to biological treatment.


Disclosure:

K. Okamura,
None;

Y. Yonemoto,
None;

T. Kaneko,
None;

K. Takeuchi,
None;

T. Kobayashi,
None;

K. Takagishi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fdg-pet-evaluation-of-axillary-lymph-nodes-and-large-joints-of-patients-with-rheumatoid-arthritis-treated-with-anti-tnf-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology